CA1071105A - Augmentation de la concentration de l'aspirine dans le sang - Google Patents

Augmentation de la concentration de l'aspirine dans le sang

Info

Publication number: CA1071105A
Authority: CA; Canada
Prior art keywords: asa; apap; grains; blood; blood levels
Prior art date: 1976-04-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA264,436A

Other languages

English (en)

Inventor

Val F. Cotty

Francis J. Sterbenz

Kenneth J. Melman

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bristol Myers Squibb Co

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1976-04-26

Filing date

1976-10-29

Publication date

1980-02-05

1976-10-29 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

1980-02-05 Application granted granted Critical

1980-02-05 Publication of CA1071105A publication Critical patent/CA1071105A/fr

Status Expired legal-status Critical Current

Links

BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 title claims abstract description 119
229960001138 acetylsalicylic acid Drugs 0.000 title claims description 10
230000036765 blood level Effects 0.000 title abstract description 19
230000003416 augmentation Effects 0.000 title description 3
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims abstract description 61
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims abstract description 28
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims abstract description 16
229960001948 caffeine Drugs 0.000 claims abstract description 14
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims abstract description 14
229960005489 paracetamol Drugs 0.000 claims abstract description 8
239000000203 mixture Substances 0.000 claims description 24
230000037406 food intake Effects 0.000 abstract description 5
208000029618 autoimmune pulmonary alveolar proteinosis Diseases 0.000 description 52
210000004369 blood Anatomy 0.000 description 18
239000008280 blood Substances 0.000 description 18
230000000694 effects Effects 0.000 description 8
238000000034 method Methods 0.000 description 7
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 7
229940079593 drug Drugs 0.000 description 6
239000003814 drug Substances 0.000 description 6
238000010521 absorption reaction Methods 0.000 description 5
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 4
239000002775 capsule Substances 0.000 description 4
239000011734 sodium Substances 0.000 description 4
229910052708 sodium Inorganic materials 0.000 description 4
229960004025 sodium salicylate Drugs 0.000 description 4
238000012360 testing method Methods 0.000 description 4
229920002261 Corn starch Polymers 0.000 description 3
239000002253 acid Substances 0.000 description 3
239000008120 corn starch Substances 0.000 description 3
230000002440 hepatic effect Effects 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
239000000843 powder Substances 0.000 description 3
229960001860 salicylate Drugs 0.000 description 3
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 3
229960004889 salicylic acid Drugs 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
241000282412 Homo Species 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
101100366940 Mus musculus Stom gene Proteins 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
229940035676 analgesics Drugs 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000000730 antalgic agent Substances 0.000 description 2
230000003190 augmentative effect Effects 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
238000000605 extraction Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
239000008101 lactose Substances 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
238000002483 medication Methods 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
241001337993 Agathis <wasp> Species 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
206010013710 Drug interaction Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
206010053155 Epigastric discomfort Diseases 0.000 description 1
206010015150 Erythema Diseases 0.000 description 1
206010017788 Gastric haemorrhage Diseases 0.000 description 1
AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
244000180577 Sambucus australis Species 0.000 description 1
235000018734 Sambucus australis Nutrition 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000011149 active material Substances 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
229940069428 antacid Drugs 0.000 description 1
239000003159 antacid agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000001754 anti-pyretic effect Effects 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
239000002221 antipyretic Substances 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
210000001772 blood platelet Anatomy 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
229960003291 chlorphenamine Drugs 0.000 description 1
230000004087 circulation Effects 0.000 description 1
239000011436 cob Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000006196 deacetylation Effects 0.000 description 1
238000003381 deacetylation reaction Methods 0.000 description 1
239000000850 decongestant Substances 0.000 description 1
229940124581 decongestants Drugs 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
229960004193 dextropropoxyphene Drugs 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
-1 lubrlcant~ Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
HNJJXZKZRAWDPF-UHFFFAOYSA-N methapyrilene Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CS1 HNJJXZKZRAWDPF-UHFFFAOYSA-N 0.000 description 1
229960001869 methapyrilene Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
229960001802 phenylephrine Drugs 0.000 description 1
SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
229960000395 phenylpropanolamine Drugs 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
150000003873 salicylate salts Chemical class 0.000 description 1
239000002002 slurry Substances 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
241000894007 species Species 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
RQAITHJHUFFEIV-UHFFFAOYSA-N thurfyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1CCCO1 RQAITHJHUFFEIV-UHFFFAOYSA-N 0.000 description 1
229950006036 thurfyl nicotinate Drugs 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
- A61K31/621—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate having the hydroxy group in position 2 esterified, e.g. benorylate

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

CA264,436A 1976-04-26 1976-10-29 Augmentation de la concentration de l'aspirine dans le sang Expired CA1071105A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US05/680,307 US4049803A (en)	1976-04-26	1976-04-26	Augmentation of blood levels of aspirin

Publications (1)

Publication Number	Publication Date
CA1071105A true CA1071105A (fr)	1980-02-05

Family

ID=24730572

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA264,436A Expired CA1071105A (fr)	1976-04-26	1976-10-29	Augmentation de la concentration de l'aspirine dans le sang

Country Status (2)

Country	Link
US (1)	US4049803A (fr)
CA (1)	CA1071105A (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL175882C (nl) *	1977-03-28		Procter & Gamble	Farmaceutisch preparaat, dat een verbinding met ontstekingtegengaande werking bevat.
US4275059A (en) *	1977-03-28	1981-06-23	The Procter & Gamble Company	Salicylate anti-inflammatory composition
WO1979000556A1 (fr) *	1978-01-27	1979-08-23	E Zobian	Composition renfermant de l'acide salicylsalicylique et de l'acetaminophene
US4505862A (en) *	1981-04-14	1985-03-19	Bristol-Myers Company	Diphenydramine dihydrogencitrate
DE3348444C2 (de) *	1982-07-22	1995-02-02	Richardson Vicks Inc	Analgetische und antiinflammatorische Mittel
US4507276A (en) *	1982-08-20	1985-03-26	Bristol-Myers Company	Analgesic capsule
GB8325627D0 (en) *	1983-09-24	1983-10-26	Scras	Therapeutic compositions
AU676315B2 (en) *	1993-06-30	1997-03-06	Takeda Chemical Industries Ltd.	Stabilized solid pharmaceutical preparation and method of producing the same
IL155514A0 (en) *	2000-10-20	2003-11-23	Tsuneya Ohno	Fusion cells and cytokine compositions for treatment of disease
US6596708B1 (en)	2001-09-07	2003-07-22	Advanced Medical Instruments	Composition for the treatment and prevention of endothelial dysfunction
US20050065172A1 (en) *	2003-09-23	2005-03-24	Shah Indukumar G.	Solid dosage form comprising caffeine
US20070249727A1 (en)	2006-04-21	2007-10-25	The Proctor & Gamble Company	Compositions and kits useful for treatment of respiratory illness
US10022339B2 (en)	2006-04-21	2018-07-17	The Procter & Gamble Company	Compositions and methods useful for treatment of respiratory illness
US20110268798A1 (en) *	2009-01-16	2011-11-03	Add Advanced Drug Delivery Technologies Ltd	Orally disntegrating tablets for the treatment of pain
EP3086793B1 (fr)	2013-12-24	2022-05-11	Virginia Commonwealth University	Utilisations de sulfates de cholestérol oxygénés (ocs) pour le traitement du dysfonctionnement du rein

1976
- 1976-04-26 US US05/680,307 patent/US4049803A/en not_active Expired - Lifetime
- 1976-10-29 CA CA264,436A patent/CA1071105A/fr not_active Expired

Also Published As

Publication number	Publication date
US4049803A (en)	1977-09-20

Legal Events

Date	Code	Title	Description
1997-02-05	MKEX	Expiry

Publication	Publication Date	Title
US4309406A (en)	1982-01-05	Sustained release pharmaceutical compositions
CA1071105A (fr)	1980-02-05	Augmentation de la concentration de l'aspirine dans le sang
US4309405A (en)	1982-01-05	Sustained release pharmaceutical compositions
US5609884A (en)	1997-03-11	Controlled release naproxen sodium plus naproxen combination tablet
US4753801A (en)	1988-06-28	Sustained release tablets
US4765990A (en)	1988-08-23	Sustained-release nifedipine preparation
KR100891887B1 (ko)	2009-04-03	5-메틸-1-페닐-2-(1ｈ)-피리돈을 활성 성분으로서 함유하는의약 제제
KR880002673B1 (ko)	1988-12-20	진통 캡슐제와 그 제조방법
KR100202154B1 (ko)	1999-06-15	파라세타몰 및 돔페리돈을 함유한 필름 피복 정제
AU676315B2 (en)	1997-03-06	Stabilized solid pharmaceutical preparation and method of producing the same
WO2003041700A1 (fr)	2003-05-22	Formulations de medicament actif de thyroxine stables au stockage
US4859469A (en)	1989-08-22	Novel galenic forms of verapamil, their preparation and medicines containing said novel galenic forms
US4888343A (en)	1989-12-19	Pharmaceutical compositions for relief of dysmenorrhea and/or premenstrual syndrome and process
BR112020004045A2 (pt)	2020-09-01	formas de dosagem de elevada concentração de pridopidina
US3524910A (en)	1970-08-18	Sustained relief analgesic compositions
PL190988B1 (pl)	2006-02-28	Preparat tabletki lub kapsułki do połykania i sposób ich wytwarzania
KR100846945B1 (ko)	2008-07-17	파라세타몰을 포함하는 연하 정제
US3865935A (en)	1975-02-11	Tableting of erythromycin base
US7052717B2 (en)	2006-05-30	Storage stable thyroxine active drug formulations and methods for their production
EP0320550A1 (fr)	1989-06-21	Composition NSAID contenant des bloqueurs H1, bloqueurs H2, agonistes bêta-adrénergiques ou leurs mélanges et un agent alcalinisant
JPH0157090B2 (fr)	1989-12-04
CA1182049A (fr)	1985-02-05	Compose d'apap et d'antiacide
US5156849A (en)	1992-10-20	Pharmaceutical composition
HU225779B1 (en)	2007-08-28	Pharmaceutical composition containing paracetamol and drotaverine and process for producing it
GB2061111A (en)	1981-05-13	Long acting pharmaceutical composition